Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00142467 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT00142467: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT00142467 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00142467, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of bevacizumab when given in combination with gemcitabine and oxaliplatin and to see what effects (good or bad) it has on patients with hepatocellular carcinoma.
Interventions
- DRUG Bevacizumab
- DRUG Oxaliplatin
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2004-04 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00142467
The ClinicalTrials.gov registry entry for NCT00142467 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT00142467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00142467 about?
NCT00142467 is a clinical study titled "Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma". The purpose of this study is to test the safety of bevacizumab when given in combination with gemcitabine and oxaliplatin and to see what effects (good or bad) it has on patients with hepatocellular carcinoma.
What is the current status of trial NCT00142467?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2004-04. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00142467?
The interventions under investigation include: Bevacizumab (DRUG), Oxaliplatin (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00142467?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.